Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - AB 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 43260.14 
• Atom Count: 3024 
• Residue Count: 370 
• Unique protein chains: 2

1Q8T

The Catalytic Subunit of cAMP-dependent Protein Kinase (PKA) in Complex with Rho-kinase Inhibitor Y-27632

• DOI: 10.2210/pdb1Q8T/pdb

• Classification: Transferase/Transferase Inhibitor
• Organism(s): Bos taurus, Homo sapiens
• Expression System: Escherichia coli BL21(DE3)


• Deposited: 2003-08-22 Released: 2003-12-16 
• Deposition Author(s): Breitenlechner, C., Gassel, M., Hidaka, H., Kinzel, V., Huber, R., Engh, R.A., Bossemeyer, D.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2 Å
• R-Value Free: 0.229 
• R-Value Work: 0.176 

Literature

Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity.

Breitenlechner, C., Gassel, M., Hidaka, H., Kinzel, V., Huber, R., Engh, R.A., Bossemeyer, D.

(2003) Structure 11: 1595-1607

• PubMed: 14656443 
• Primary Citation of Related Structures:  
  1Q8W, 1Q8U
• Also Cited By: 2GNJ, 2GNL, 2GNI, 2GNH, 2GNG, 2GNF


• PubMed Abstract: 
  

Protein kinases require strict inactivation to prevent spurious cellular signaling; overactivity can cause cancer or other diseases and necessitates selective inhibition for therapy. Rho-kinase is involved in such processes as tumor invasion, cell adhesion, smooth muscle contraction, and formation of focal adhesion fibers, as revealed using inhibitor Y-27632. Another Rho-kinase inhibitor, HA-1077 or Fasudil, is currently used in the treatment of cerebral vasospasm; the related nanomolar inhibitor H-1152P improves on its selectivity and potency. We have determined the crystal structures of HA-1077, H-1152P, and Y-27632 in complexes with protein kinase A (PKA) as a surrogate kinase to analyze Rho-kinase inhibitor binding properties. Features conserved between PKA and Rho-kinase are involved in the key binding interactions, while a combination of residues at the ATP binding pocket that are unique to Rho-kinase may explain the inhibitors' Rho-kinase selectivity. Further, a second H-1152P binding site potentially points toward PKA regulatory domain interaction modulators.

---

Organizational Affiliation: 

Abteilung Strukturforschung, Max-Planck-Institut fuer Biochemie, 82152 Martinsried, Germany.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
cAMP-dependent protein kinase, alpha-catalytic subunit	A	350	Bos taurus	Mutation(s): 0  Gene Names: PRKACA EC: 2.7.11.11
Find proteins for P00517 (Bos taurus) Go to Gene View: PRKACA Go to UniProtKB:  P00517

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details
cAMP-dependent protein kinase inhibitor, alpha form	B	20	Homo sapiens	Mutation(s): 0  Gene Names: PKIA (PRKACN1)
Find proteins for P61925 (Homo sapiens) Go to Gene View: PKIA Go to UniProtKB:  P61925

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
Y27	A	(R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE C14 H21 N3 O IYOZTVGMEWJPKR-IJLUTSLNSA-N

Modified Residues  2 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
SEP	A	L-PEPTIDE LINKING	C3 H8 N O6 P		SER
TPO	A	L-PEPTIDE LINKING	C4 H10 N O6 P		THR

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
Y27	IC50: 6000 - 60000 nM (99) BINDINGDB
Y27	Ki: >5000 - >10000 nM (97) BINDINGDB
Y27	Kd: 17500 nM BINDINGMOAD
Y27	Kd: 17500 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2 Å
• R-Value Free: 0.229 
• R-Value Work: 0.176 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length (Å)	Angle (°)
a = 74.027	α = 90.00
b = 76.606	β = 90.00
c = 80.700	γ = 90.00

Software Package:

Software Name	Purpose
MOSFLM	data reduction
REFMAC	refinement
CCP4	data scaling
AMoRE	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2003-08-22 
• Released Date: 2003-12-16 
• Deposition Author(s): Breitenlechner, C., Gassel, M., Hidaka, H., Kinzel, V., Huber, R., Engh, R.A., Bossemeyer, D.

Revision History 

• Version 1.0: 2003-12-16
  Type: Initial release
• Version 1.1: 2008-04-29
  Type: Version format compliance
• Version 1.2: 2011-07-13
  Type: Version format compliance